Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Pharmather Hldgs Ltd (PHRRF)

Pharmather Hldgs Ltd (PHRRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application GlobeNewswire - Wed Nov 13, 7:00AM CST

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application GlobeNewswire - Wed Oct 23, 7:00AM CDT

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases Newsfile - Wed Aug 28, 7:10AM CDT

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...

PHRRF : 0.1600 (+5.54%)
LMLLF : 0.0142 (+12.70%)
PHRM.CN : 0.2200 (+2.33%)
PHRX.CN : 0.0200 (+33.33%)
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders Globe Newswire - Wed Jul 13, 2022

TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1600 (+5.54%)
PHRM.CN : 0.2200 (+2.33%)
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch Globe Newswire - Wed Jun 29, 2022

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO Globe Newswire - Wed May 25, 2022

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update Globe Newswire - Mon Apr 25, 2022

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs Globe Newswire - Tue Apr 12, 2022

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1600 (+5.54%)
PHRM.CN : 0.2200 (+2.33%)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease Globe Newswire - Wed Mar 23, 2022

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.2200 (+2.33%)
PHRRF : 0.1600 (+5.54%)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation Globe Newswire - Wed Feb 16, 2022

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1600 (+5.54%)
PHRM.CN : 0.2200 (+2.33%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside? Barchart - Mon Nov 18, 6:30PM CST
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot